Investor Presentaiton

Kerecis is transforming wound healing with its clinically differentiated technology platform based on gently processed fish skin Kerecis key business highlights Revenue for FY 2021/22 Revenue distribution by wound type Started in 2009, with headquarters and manufacturing in Iceland Proprietary product platform based on cod fish skin DKK 510m DKK 1m EBIT FY 2021/22 -10% Only FDA-approved manufacturer of patented fish-skin technology Fastest growing company in the biologics wound care segment with strong US presence 98% of sales within the US -30% -5% market share in the US biologics segment -60% -500 employees globally Sustainable business with a unique waste-to-value proposition, minimal processing, and production run on 100% green energy >2/3 of employees in the US >20.000 patients globally treated with the novel fish skin technology Chronic Burn Surgical Core values rooted in Nordic heritage: compassion, curiosity and integrity Kerecis projected revenue growth and profitability expansion Kerecis revenue development, DKKm Kerecis product portfolio 49 -30% 3Y CAGR -50% 510 FY FY FY 21/22 22/23E 25/26E EBIT margin: -10% -20% *MariGen OSPITAL OU Express PRIVATE *Shield Standard OFFICE Shield Adhesive Conte Shield MariGen GraftGuide tGuide Express Manus BURN SurgiClose SurgiBind rgiClose SurgiClose Surg Micro Express SURGICAL *Launch pending Coloplast

View entire presentation